基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 TC-SP 14 化合物 TC-SP 14
  • 化合物 TC-SP 14|T21916|TargetMol

化合物 TC-SP 14|T21916|TargetMol

TC-SP 14
1257093-40-5
￥13800 50mg 起订
￥10600 25mg 起订
￥17500 100mg 起订
上海 更新日期：2025-11-17

TargetMol中国（陶术生物）

VIP4年
联系人：邵小姐
手机：4008200310 拨打
邮箱：marketing@tsbiochem.com

产品详情:

中文名称：
化合物 TC-SP 14
英文名称：
TC-SP 14
CAS号：
1257093-40-5
品牌：
TargetMol
产地：
美国
保存条件：
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
产品类别：
抑制剂
货号：
T21916

Product Introduction

Bioactivity

名称TC-SP 14
描述TC-SP 14, also known as compound 14, is a highly active and potent S1P1 agonist with oral bioavailability. It exhibits an EC50 value of 0.042 μM, indicating its strong binding affinity to the S1P1 receptor. Notably, its interaction with the S1P3 receptor is minimal, as evidenced by an EC50 value of 3.47 μM. TC-SP 14 demonstrates significant pharmacological effects, including a marked reduction in blood lymphocyte counts and the attenuation of delayed type hypersensitivity response to antigen challenge [1].
体外活性TC-SP 14 (compound 14) neither inhibits nor induces human cytochrome P450 enzymes. TC-SP 14 is nonmutagenic and does not significantly inhibit the hERG channel [1].
体内活性TC-SP 14 (compound 14) (0-3 mg/kg, Orally, once) produces a dose-dependent reduction in circulating blood lymphocytes 24 h after dosing [1]. TC-SP 14 (0-3 mg/kg, Orally, daily for 10 days) significant reduces ovalbumin (OVA)-induced ear swelling [1]. TC-SP 14 (2-15 mg/kg, IV or PO, once) possesses acceptable characteristics [1]. Pharmacokinetic Parameters of TC-SP 14 in female Sprague-Dawley rats and male Cynomolgus [1]. species rat NHP CL (L/h/kg) 0.33 0.50 Vss (L/kg) 3.3 1.6 T 1/2 (h) 7.5 35.2 MRT (h) 10 3.3 % F 68 23 Animal Model: Lewis rats (female, n = 5/group) [1] Dosage: 0.3, 1.0, and 3.0 mg/kg Administration: Orally, once Result: Produced a dose-dependent reduction in circulating blood lymphocytes 24 h postdose, resulted in near maximal lymphopenia at 3.0 mg/kg (74% reduction in lymphocytes vs vehicle). Animal Model: OVA-immunized Lewis rats (female, n = 8/group) [1] Dosage: 0.1, 0.3, 1.0, and 3.0 mg/kg Administration: Orally, daily for 10 days Result: Significant reduced OVA-induced ear swelling at doses of 0.3 mg/kg and higher. Animal Model: Female Sprague-Dawley rats, Male Cynomolgus (NHP (nonhuman primates)) (n=3/group) [1] Dosage: 2 (IV, rat), 4 (IV, NHP), 10 (PO, NHP), 15 mg/kg (PO, rat) Administration: IV, PO, once (Pharmacokinetic Analysis) Result: Possessed acceptable characteristics, demonstrated low clearance, moderate steady state volumes of distribution, moderate-to-long mean residence times, and acceptable oral bioavailability.
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
关键字TCSP 14 | TC SP 14 | TC-SP 14
相关产品Poloxamer 407 | Sphingosine-1-phosphate | S1PR1 modulator 1 | Siponimod | LX-2931 | Tyloxapol | Ki16198 | CAY10444 | CYM5181 | Fingolimod hydrochloride | CYM50374 | ASP-4058
TC-SP 14|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期 (13年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ￥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 TC-SP 14相关厂家报价

内容声明
official 进入官方账号
拨打电话 立即询价